Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890561308> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- W2890561308 abstract "Abstract Background The 8th edition of the American Joint Committee on Cancer staging (AJCC-8th) of esophageal cancer presents independent stage grouping for patients who underwent neoadjuvant therapy followed by esophagectomy (ypTNM). The aim of this study is to elucidate the clinical utility of ypTNM stage grouping in Japanese patients with esophageal squamous cell carcinoma (ESCC). Methods A total of 146 patients (121 men and 25 women, with a median age of 65 years) who underwent curative esophagectomy following neoadjuvant chemotherapy with cisplatin and 5-fluorouracil (CF) for ESCC between 2005 and 2011 were enrolled in this retrospective study. We compared the distribution of patients and disease-specific survival after esophagectomy (DSS) stratified by ypStage between AJCC-7th and 8th. Additionally, we evaluated the association between clinicopathological features including ypStage in AJCC-8th and DSS. Results The number of patients classified into ypStage 0/IA/IB/IIA/IIB/IIIA/IIIB/IIIC/IV was 5/1/14/11/35/40/18/18/4 in AJCC-7th, and that classified into ypStage I/II/IIIA/IIIB/IVA/IVB was 27/18/21/58/18/4 in AJCC-8th. According to the revision from AJCC-7th to 8th, ypStage of 85 and 7 patients was up- and down-graded, respectively. Up-grading of ypStage was observed in 83% of patients with ypT4 tumor and in 78% of patients with ypN1–3. The 5-year DSS of ypStage 0/IA/IB/IIA/IIB/IIIA/IIIB/IIIC/IV was 100/100/93/91/75/62/50/28/50% in AJCC-7th, and that of ypStage I/II/IIIA/IIIB/IVA/IVB was 96/83/68/58/28/50% in AJCC-8th. The 5-year DSS of ypStage III was 61% in AJCC-8th comparing to 51% in AJCC-7th, and that of ypStage IV was 31% in AJCC-8th comparing to 50% in AJCC-7th. Univariate analyses identified ypT-8th (P = 0.028), ypN-8th (P < 0.001), cStage-8th (P = 0.006) and ypStage-8th (P < 0.001) in addition to surgical procedure (P = 0.027) and histological response (P = 0.019) as significant prognostic factors for DSS. Among these, multivariate analysis showed that ypStage-8th was a significant independent prognostic factor for DSS (P < 0.001). Conclusion ypTNM stage grouping in AJCC-8th can more accurately stratify the prognosis of patients who underwent neoadjuvant CF therapy for ESCC, by classifying patients with residual tumor invasion to adjacent structures and regional lymph node metastasis into more unfavorable prognostic group than that in AJCC-7th. ypStage according to AJCC-8th is the most reliable prognosticator for this disease. Disclosure All authors have declared no conflicts of interest." @default.
- W2890561308 created "2018-09-27" @default.
- W2890561308 creator A5000385500 @default.
- W2890561308 creator A5019278166 @default.
- W2890561308 creator A5025995147 @default.
- W2890561308 creator A5027914167 @default.
- W2890561308 creator A5036289394 @default.
- W2890561308 creator A5037996991 @default.
- W2890561308 creator A5052803318 @default.
- W2890561308 creator A5061189316 @default.
- W2890561308 creator A5062609402 @default.
- W2890561308 creator A5064551187 @default.
- W2890561308 creator A5067160675 @default.
- W2890561308 creator A5081160218 @default.
- W2890561308 creator A5087348287 @default.
- W2890561308 date "2018-09-01" @default.
- W2890561308 modified "2023-09-26" @default.
- W2890561308 title "FA06.06: CLINICAL UTILITY OF YPTNM STAGE GROUPING IN AJCC 8TH EDITION FOR JAPANESE PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA" @default.
- W2890561308 doi "https://doi.org/10.1093/dote/doy089.fa06.06" @default.
- W2890561308 hasPublicationYear "2018" @default.
- W2890561308 type Work @default.
- W2890561308 sameAs 2890561308 @default.
- W2890561308 citedByCount "0" @default.
- W2890561308 crossrefType "journal-article" @default.
- W2890561308 hasAuthorship W2890561308A5000385500 @default.
- W2890561308 hasAuthorship W2890561308A5019278166 @default.
- W2890561308 hasAuthorship W2890561308A5025995147 @default.
- W2890561308 hasAuthorship W2890561308A5027914167 @default.
- W2890561308 hasAuthorship W2890561308A5036289394 @default.
- W2890561308 hasAuthorship W2890561308A5037996991 @default.
- W2890561308 hasAuthorship W2890561308A5052803318 @default.
- W2890561308 hasAuthorship W2890561308A5061189316 @default.
- W2890561308 hasAuthorship W2890561308A5062609402 @default.
- W2890561308 hasAuthorship W2890561308A5064551187 @default.
- W2890561308 hasAuthorship W2890561308A5067160675 @default.
- W2890561308 hasAuthorship W2890561308A5081160218 @default.
- W2890561308 hasAuthorship W2890561308A5087348287 @default.
- W2890561308 hasConcept C126322002 @default.
- W2890561308 hasConcept C143998085 @default.
- W2890561308 hasConcept C146357865 @default.
- W2890561308 hasConcept C151730666 @default.
- W2890561308 hasConcept C2777546739 @default.
- W2890561308 hasConcept C2994415158 @default.
- W2890561308 hasConcept C3019992690 @default.
- W2890561308 hasConcept C71924100 @default.
- W2890561308 hasConcept C86803240 @default.
- W2890561308 hasConceptScore W2890561308C126322002 @default.
- W2890561308 hasConceptScore W2890561308C143998085 @default.
- W2890561308 hasConceptScore W2890561308C146357865 @default.
- W2890561308 hasConceptScore W2890561308C151730666 @default.
- W2890561308 hasConceptScore W2890561308C2777546739 @default.
- W2890561308 hasConceptScore W2890561308C2994415158 @default.
- W2890561308 hasConceptScore W2890561308C3019992690 @default.
- W2890561308 hasConceptScore W2890561308C71924100 @default.
- W2890561308 hasConceptScore W2890561308C86803240 @default.
- W2890561308 hasLocation W28905613081 @default.
- W2890561308 hasOpenAccess W2890561308 @default.
- W2890561308 hasPrimaryLocation W28905613081 @default.
- W2890561308 isParatext "false" @default.
- W2890561308 isRetracted "false" @default.
- W2890561308 magId "2890561308" @default.
- W2890561308 workType "article" @default.